GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fresenius Medical Care AG (NYSE:FMS) » Definitions » Debt-to-EBITDA

Fresenius Medical Care AG (Fresenius Medical Care AG) Debt-to-EBITDA : 3.42 (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is Fresenius Medical Care AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fresenius Medical Care AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,703 Mil. Fresenius Medical Care AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $11,438 Mil. Fresenius Medical Care AG's annualized EBITDA for the quarter that ended in Dec. 2023 was $3,841 Mil. Fresenius Medical Care AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 3.42.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Fresenius Medical Care AG's Debt-to-EBITDA or its related term are showing as below:

FMS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.9   Med: 3.06   Max: 3.86
Current: 3.75

During the past 13 years, the highest Debt-to-EBITDA Ratio of Fresenius Medical Care AG was 3.86. The lowest was 1.90. And the median was 3.06.

FMS's Debt-to-EBITDA is ranked worse than
63.01% of 419 companies
in the Healthcare Providers & Services industry
Industry Median: 2.57 vs FMS: 3.75

Fresenius Medical Care AG Debt-to-EBITDA Historical Data

The historical data trend for Fresenius Medical Care AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresenius Medical Care AG Debt-to-EBITDA Chart

Fresenius Medical Care AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.51 3.00 3.75 3.86 3.75

Fresenius Medical Care AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.79 4.67 4.01 4.04 3.42

Competitive Comparison of Fresenius Medical Care AG's Debt-to-EBITDA

For the Medical Care Facilities subindustry, Fresenius Medical Care AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresenius Medical Care AG's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fresenius Medical Care AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fresenius Medical Care AG's Debt-to-EBITDA falls into.



Fresenius Medical Care AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Fresenius Medical Care AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1702.903 + 11438.222) / 3500.137
=3.75

Fresenius Medical Care AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1702.903 + 11438.222) / 3840.548
=3.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Fresenius Medical Care AG  (NYSE:FMS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Fresenius Medical Care AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fresenius Medical Care AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresenius Medical Care AG (Fresenius Medical Care AG) Business Description

Address
Else-Kroener-Strasse 1, Bad Homburg, HE, DEU, 61352
Fresenius Medical Care is the largest dialysis company in the world, treating about 345,000 patients from over 4,100 clinics across the globe as of December 2022. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market and benefits from being the world's only fully integrated dialysis business. Services account for roughly 80% of firmwide revenue, including care coordination and ancillary operations, while products account for the other roughly 20%. Products typically enjoy a higher margin, making them a strong contributor to the bottom line.
Executives
Helen Pring Giza Board of Directors